Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2019 Jun;138:60-69. doi: 10.1016/j.critrevonc.2019.03.019. Epub 2019 Apr 4.

Immune check-point in glioblastoma multiforme.

Author information

1
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy. Electronic address: fradefelice@hotmail.it.
2
Department of Oral and Maxillo Facial Sciences, Policlinico Umberto I "Sapienza" University of Rome, Italy.
3
Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Rome, Italy.
4
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Abstract

Glioblastoma multiforme (GBM) represents one of the main frequent and aggressive primary brain neoplasms among adults worldwide. Despite a first-line multimodal treatment, including radical surgery and adjuvant radiation therapy with concomitant temozolomide-based chemotherapy, GBM prognosis continues to be unfavourable. During this decade, different research groups have explored immune check-point inhibitors role in order to improve response to therapy and subsequently prolong survival rate. The aim of this review was to analyze published literature to support immune check-point inhibitors use in the management of patients with GBM diagnosis. The hope was to help physicians for better decision-making.

KEYWORDS:

Benefit; Glioblastoma; Immune check-point; Immunotherapy; Survival

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center